Zimbabwe has turned down a significant US healthcare agreement worth 367 million US dollars (272 million pounds) over five years due to Washington's insistence on sensitive data.
This move became public following a official document from December was disclosed, which showed President Emmerson Mnangagwa deemed the agreement was "unbalanced".
An official spokesperson later stated that the US was demanding access to genetic material for scientific study and commercial purposes but refused to share the resulting advantages from future medical innovations.
"We are forced to start the challenging and unfortunate task of winding down our health assistance in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy noted the United States had donated more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for continued talks to find a deal acceptable to both sides so the country's vital HIV treatment initiative can proceed.
Broader Context
This development follows a comparable case in neighbouring Kenya, where a court suspended a related deal with the US following concerns were raised about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
The agency had managed assistance for the US government, but Trump claimed its expenditure was "inefficient" and his government was pursuing government-to-government deals to boost transparency and responsibility.
As per reports, 16 African countries have so far signed these new agreements, representing more than $18.3bn of fresh investment.
Details of the Rejected Agreement
This assistance for Zimbabwe would have funded "tackling HIV/Aids, tuberculosis, malaria, maternal and child health, and preparing for epidemics".
"We are confident this collaboration could have provided immense advantages for the people of Zimbabwe, particularly the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont added.
However, official spokesman Nick Mangwana said the arrangement was "asymmetrical".
"The proposal required Zimbabwe to share its biological resources and data for a long time, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could result from that shared data," he stated.
"Put simply, our country would supply the raw materials for medical research with no assurance that the resulting innovations would be available to our citizens should a future disease outbreak arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of bilateral health agreements were undermining frameworks previously set up via the international health agency.
The spokesperson cited its Pandemic Benefit-Sharing scheme created to deal with potential pandemics.
"This system is designed to ensure that when a nation provides its data, the benefits – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We encourage ongoing dialogue with our US partners on how subsequent collaboration might be designed in a way that respects the independence and dignity of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it acknowledged the government's concerns, but recommended that talks need to persist considering a large portion of the nation's Aids initiatives were funded by foreign aid.
"Where technical issues exist, such as those relating to information security or implementation frameworks, these can often be addressed via technical clarification and mutually agreed protections," it added.
This impasse underscores the continuing challenges between receiving vital foreign assistance and protecting local interests in an ever more data-driven world.